Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Bangkok Lab and Cosmetic PCL EV-to-EBITDA?
Bangkok Lab and Cosmetic PCLBKK:BLC +0.51%63 EV-to-EBITDA is 10.99 as of Aug. 22, 2026, which is 28% above its 10-year median of 8.57. GuruFocus rates BKK:BLC with a GF Score™ of 63/100 and a GF Value™ of ฿4.74 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,645 Consumer Packaged Goods companies, Bangkok Lab and Cosmetic PCL ranks worse than 60.36% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bangkok Lab and Cosmetic PCL's enterprise value is ฿2,694 Mil.
Bangkok Lab and Cosmetic PCL's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ฿245 Mil. Therefore, Bangkok Lab and Cosmetic PCL's EV-to-EBITDA for today is 10.99.
The historical rank and industry rank for Bangkok Lab and Cosmetic PCL's EV-to-EBITDA or its related term are showing as below:
BKK:BLC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.26 Med: 8.57 Max: 21.3
Current: 10.99
During the past 5 years, the highest EV-to-EBITDA of Bangkok Lab and Cosmetic PCL was 21.30. The lowest was 5.26. And the median was 8.57.
BKK:BLC's EV-to-EBITDA is ranked worse than 60.36% of 1645
companies
in the Consumer Packaged Goods industry
Industry Median: 9.11
vs BKK:BLC: 10.99
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Bangkok Lab and Cosmetic PCL (BKK:BLC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bangkok Lab and Cosmetic PCL's PE Ratio (TTM) for today is calculated as:
Bangkok Lab and Cosmetic PCL's share price for today is ฿3.92.
Bangkok Lab and Cosmetic PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0.233.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Bangkok Lab and Cosmetic PCL's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Lab and Cosmetic PCL EV-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Bangkok Lab and Cosmetic PCL's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bangkok Lab and Cosmetic PCL's EV-to-EBITDA falls into.
Bangkok Lab and Cosmetic PCL's current Enterprise Value is ฿2,694 Mil.
Bangkok Lab and Cosmetic PCL's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿245 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bangkok Lab and Cosmetic PCL (BKK:BLC) has a EV-to-EBITDA of 10.99 as of Aug. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bangkok Lab and Cosmetic PCL. This is 28% above median its historical median of 8.57. Over the past decade, Bangkok Lab and Cosmetic PCL's EV-to-EBITDA has ranged from 5.26 to 21.30. According to the industry distribution chart, Bangkok Lab and Cosmetic PCL ranks #993 out of 1645 companies in the Consumer Packaged Goods industry, placing it in the top 60.4%.
Is Bangkok Lab and Cosmetic PCL's EV-to-EBITDA too high?
Bangkok Lab and Cosmetic PCL's current EV-to-EBITDA of 10.99 is 28% above median its 10-year median of 8.57. Over the past 10 years, this metric has ranged from a low of 5.26 to a high of 21.30. The Consumer Packaged Goods industry median EV-to-EBITDA is 9.11. Bangkok Lab and Cosmetic PCL's value of 10.99 is 20.6% above this industry median. Based on the distribution chart, Bangkok Lab and Cosmetic PCL ranks #993 out of 1645 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Bangkok Lab and Cosmetic PCL has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bangkok Lab and Cosmetic PCL's EV-to-EBITDA compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Bangkok Lab and Cosmetic PCL ranks #993 out of 1645 companies for EV-to-EBITDA. This places Bangkok Lab and Cosmetic PCL in the lower half of its industry. The industry median EV-to-EBITDA is 9.11. Bangkok Lab and Cosmetic PCL's value of 10.99 is 20.6% above this benchmark. Historically, Bangkok Lab and Cosmetic PCL's own EV-to-EBITDA has ranged from 5.26 to 21.30 over the past decade. While the company's 10-year median is 8.57 vs. the industry median of 9.11, Bangkok Lab and Cosmetic PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Consumer Packaged Goods company?
The median EV-to-EBITDA among Consumer Packaged Goods companies is 9.11, based on 1,645 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bangkok Lab and Cosmetic PCL's current EV-to-EBITDA of 10.99 is 20.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bangkok Lab and Cosmetic PCL. For the Consumer Packaged Goods industry, the median EV-to-EBITDA is 9.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bangkok Lab and Cosmetic PCL's current EV-to-EBITDA is 10.99, which is 28% above median its own 10-year median of 8.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Lab and Cosmetic PCL stock overvalued right now?
Based on GuruFocus' analysis, Bangkok Lab and Cosmetic PCL (BKK:BLC) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿4.74, compared to a current price of ฿3.92 — trading 17.3% below its estimated fair value. The current EV-to-EBITDA is 10.99, which is 28% above median its 10-year median of 8.57 and 20.6% above the Consumer Packaged Goods industry median of 9.11. Bangkok Lab and Cosmetic PCL's overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bangkok Lab and Cosmetic PCL (BKK:BLC), the current EV-to-EBITDA is 10.99 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bangkok Lab and Cosmetic PCL (BKK:BLC) Overvalued in 2026?
Based on GuruFocus' analysis, Bangkok Lab and Cosmetic PCL stock appears to be undervalued.
The current stock price of ฿3.92 is trading 17.3% below its estimated GF Value™ of ฿4.74.
GuruFocus considers Bangkok Lab and Cosmetic PCL to be Modestly Undervalued.
Key valuation signals for BKK:BLC:
EV-to-EBITDA: 10.99 (28% above median its 10-year median of 8.57)
GF Value™: ฿4.74 vs. price of ฿3.92 (17.3% below fair value)
Industry Position: 20.6% above the Consumer Packaged Goods median (#993 of 1645)
No single metric tells the full story. See the BKK:BLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bangkok Lab and Cosmetic PCL are one of Thailand's comprehensive healthcare solutions groups. The principal activities of the Group are the manufacturing and distributing of pharmaceuticals and medicinal chemical products for human and animal It operates in a single line of business, namely pharmaceuticals and medicinal chemical products, The Group derives revenue from sales of goods and rendering of services.
63GF Score
Get the complete analysis for BKK:BLC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BLC has been successfully added to your 
